SCCB
MCID: SML031
MIFTS: 37

Small Cell Carcinoma of the Bladder (SCCB) malady

Categories: Rare diseases, Cancer diseases, Neuronal diseases, Nephrological diseases

Aliases & Classifications for Small Cell Carcinoma of the Bladder

Aliases & Descriptions for Small Cell Carcinoma of the Bladder:

Name: Small Cell Carcinoma of the Bladder 50 56
Small Cell Bladder Cancer 50 56 69
Poorly Differentiated Neuroendocrine Carcinoma of the Bladder 50 56
Small Cell Carcinoma of the Urinary Bladder 50 56
Small Cell Bladder Carcinoma 50 56
Sccb 50 56

Characteristics:

Orphanet epidemiological data:

56
small cell carcinoma of the bladder
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult; Age of death: elderly;

Classifications:

Orphanet: 56  
Rare urogenital diseases


External Ids:

Orphanet 56 ORPHA284400

Summaries for Small Cell Carcinoma of the Bladder

MalaCards based summary : Small Cell Carcinoma of the Bladder, also known as small cell bladder cancer, is related to small cell carcinoma and peroneal nerve paralysis, and has symptoms including hematuria, abdominal pain and hypercalcemia. An important gene associated with Small Cell Carcinoma of the Bladder is CHGA (Chromogranin A), and among its related pathways/superpathways is Neuroscience. The drugs Nicotine and Fibrinolysin have been mentioned in the context of this disorder.

Related Diseases for Small Cell Carcinoma of the Bladder

Diseases related to Small Cell Carcinoma of the Bladder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 193)
id Related Disease Score Top Affiliating Genes
1 small cell carcinoma 10.5
2 peroneal nerve paralysis 10.3 CHGA SYP
3 brain stem ependymoma 10.3 CHGA SYP
4 extrahepatic biliary papillomatosis 10.3 CHGA SYP
5 epithelioid malignant peripheral nerve sheath tumor 10.3 CHGA SYP
6 cartilage cancer 10.3 CHGA SYP
7 jejunal neuroendocrine tumor 10.3 CHGA SYP
8 renal pelvis adenocarcinoma 10.3 CHGA SYP
9 barre-lieou syndrome 10.3 CHGA SYP
10 microinvasive cervical squamous cell carcinoma 10.3 CHGA SYP
11 gastric duplication cysts 10.3 CHGA SYP
12 diffuse cutaneous mastocytosis 10.3 CHGA SYP
13 adult botryoid rhabdomyosarcoma 10.2 CHGA SYP
14 sm-ahnmd 10.2 CHGA ENO2
15 hepatorenal syndrome 10.2 CHGA SYP
16 acalculous cholecystitis 10.2 CHGA SYP
17 brain stem astrocytic neoplasm 10.2 CHGA SYP
18 calcific tendinitis 10.2 CHGA SYP
19 parietal lobe neoplasm 10.2 CHGA ENO2
20 urinary tract obstruction 10.2 CHGA ENO2
21 infiltrating renal pelvis transitional cell carcinoma 10.2 ENO2 SYP
22 skeletal-extraskeletal angiomatosis 10.2 ENO2 SYP
23 dysgerminoma of ovary 10.2 CHGA SYP
24 glomus tumor 10.2 ENO2 SYP
25 acinar cell cystadenocarcinoma 10.2 CHGA SYP
26 pemphigus foliaceus 10.2 ENO2 SYP
27 autosomal recessive stickler syndrome 10.2 ENO2 SYP
28 ampullary signet ring cell adenocarcinoma 10.2 ENO2 SYP
29 spinal stenosis 10.2 CHGA ENO2
30 nephrogenic adenoma of urinary bladder 10.2 ENO2 SYP
31 cowden syndrome 3 10.2 CHGA SYP
32 blood group incompatibility 10.2 ENO2 SYP
33 thymus squamous cell carcinoma 10.2 CHGA SYP
34 testicular trophoblastic tumor 10.2 CHGA SYP
35 bone dysplasia azouz type 10.2 CHGA SYP
36 rectum leiomyoma 10.2 ENO2 SYP
37 eccrine papillary adenocarcinoma 10.2 CHGA SYP
38 gallbladder pleomorphic giant cell adenocarcinoma 10.2 ENO2 SYP
39 adult epithelioid sarcoma 10.2 ENO2 SYP
40 t-cell adult acute lymphocytic leukemia 10.2 CHGA SYP
41 thoracic benign neoplasm 10.2 ENO2 SYP
42 microsporidiosis 10.2 ENO2 SYP
43 gamma heavy chain disease 10.2 ENO2 SYP
44 diphtheria 10.2 CHGA ENO2
45 kidney disease 10.2 NKX2-1 SYP
46 rh isoimmunization 10.2 ENO2 SYP
47 vulvar alveolar soft part sarcoma 10.2 ENO2 SYP
48 inner ear cancer 10.2 CHGA SYP
49 bone deterioration disease 10.2 NKX2-1 SYP
50 lipid-rich carcinoma 10.2 CHGA ENO2

Graphical network of the top 20 diseases related to Small Cell Carcinoma of the Bladder:



Diseases related to Small Cell Carcinoma of the Bladder

Symptoms & Phenotypes for Small Cell Carcinoma of the Bladder

Human phenotypes related to Small Cell Carcinoma of the Bladder:

56 32 (show all 6)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hematuria 56 32 Very frequent (99-80%) HP:0000790
2 abdominal pain 56 32 Occasional (29-5%) HP:0002027
3 hypercalcemia 56 32 Occasional (29-5%) HP:0003072
4 bladder neoplasm 56 32 Very frequent (99-80%) HP:0009725
5 dysuria 56 32 Frequent (79-30%) HP:0100518
6 recurrent urinary tract infections 56 32 Occasional (29-5%) HP:0000010

Drugs & Therapeutics for Small Cell Carcinoma of the Bladder

Drugs for Small Cell Carcinoma of the Bladder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 261)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Fibrinolysin Approved Phase 4 9004-09-5
3
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
5 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
6 Cholinergic Agents Phase 4
7 Coagulants Phase 4,Phase 2,Phase 3
8 Neurotransmitter Agents Phase 4,Phase 2
9 Nicotinic Agonists Phase 4
10 Hemostatics Phase 4,Phase 2,Phase 3
11 Plasminogen Phase 4
12 Antifibrinolytic Agents Phase 4,Phase 2,Phase 3
13 Autonomic Agents Phase 4,Phase 2
14 Central Nervous System Stimulants Phase 4
15 lysine Nutraceutical Phase 4
16
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
17
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
18
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
19
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
20
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
21
Morphine Approved, Investigational Phase 3 57-27-2 5288826
22
Succinylcholine Approved Phase 3,Phase 1,Phase 2 306-40-1 5314
23
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
24
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
27
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
28
Cephalexin Approved, Vet_approved Phase 3 15686-71-2 27447
29
Valrubicin Approved Phase 2, Phase 3 56124-62-0 41744
30
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
31
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
32 interferons Phase 2, Phase 3,Phase 1
33 Analgesics Phase 3,Phase 1,Phase 2
34 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
35 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2
36 Immunoglobulins Phase 3,Phase 1,Phase 2
37 Anti-Infective Agents Phase 3,Phase 2,Phase 1
38 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
39 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
40 Antimetabolites Phase 3,Phase 2,Phase 1
41 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
42 Antibodies Phase 3,Phase 1,Phase 2
43 Antimitotic Agents Phase 3,Phase 1,Phase 2
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
45 Antiviral Agents Phase 3,Phase 2,Phase 1
46 pancreatic polypeptide Phase 3,Phase 1
47 Epoetin alfa Phase 3 113427-24-0
48 Alkylating Agents Phase 2, Phase 3, Phase 1, Early Phase 1
49 Mitomycins Phase 2, Phase 3, Early Phase 1
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 157)
id Name Status NCT ID Phase
1 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
2 Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology Completed NCT02653261 Phase 4
3 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
4 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00014534 Phase 3
5 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
6 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
7 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3
8 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3
9 Intravesical Adjuvant Electromotive Mitomycin-C Completed NCT01920269 Phase 2, Phase 3
10 Tranexamic Acid During Cystectomy Trial (TACT) Recruiting NCT01869413 Phase 2, Phase 3
11 Photodynamic Diagnosis (PDD) in Flexible Cystoscopy Recruiting NCT02660190 Phase 3
12 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT02807636 Phase 3
13 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3
14 Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer Terminated NCT00042887 Phase 3
15 S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer Terminated NCT00003824 Phase 3
16 Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer Terminated NCT01284348 Phase 2, Phase 3
17 Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Terminated NCT01438112 Phase 2, Phase 3
18 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
19 Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder Unknown status NCT01222676 Phase 2
20 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
21 Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients Unknown status NCT01134250 Phase 1, Phase 2
22 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
23 Sunitinib in Treating Patients With Locally Advanced Bladder Cancer Completed NCT00526656 Phase 2
24 Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer Completed NCT00005086 Phase 2
25 Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery Completed NCT00268450 Phase 2
26 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2
27 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
28 Bupropion in Helping Adults Stop Smoking Completed NCT00534001 Phase 2
29 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
30 Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer Completed NCT00101842 Phase 1, Phase 2
31 Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder Completed NCT00722553 Phase 2
32 S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy Completed NCT00066612 Phase 2
33 Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Completed NCT00005831 Phase 2
34 JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin Completed NCT01599013 Phase 2
35 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Completed NCT00478361 Phase 2
36 S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium Completed NCT00055835 Phase 2
37 S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00014144 Phase 2
38 Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract Completed NCT03159143 Phase 2
39 S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin Completed NCT00234039 Phase 2
40 Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer Completed NCT00041106 Phase 2
41 Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00238420 Phase 1, Phase 2
42 Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer Completed NCT01938573 Phase 1, Phase 2
43 Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma Completed NCT00808639 Phase 2
44 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2
45 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Completed NCT00587964 Phase 2
46 Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy Completed NCT00919061 Phase 2
47 Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium Recruiting NCT00756639 Phase 2
48 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2
49 A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Recruiting NCT01928394 Phase 1, Phase 2
50 Study of Tumour Focused Radiotherapy for Bladder Cancer Recruiting NCT02447549 Phase 2

Search NIH Clinical Center for Small Cell Carcinoma of the Bladder

Genetic Tests for Small Cell Carcinoma of the Bladder

Anatomical Context for Small Cell Carcinoma of the Bladder

Publications for Small Cell Carcinoma of the Bladder

Articles related to Small Cell Carcinoma of the Bladder:

(show all 34)
id Title Authors Year
1
A Case of Primary Small-Cell Carcinoma of the Bladder. ( 27920687 )
2016
2
Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. ( 27991416 )
2016
3
Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. ( 26679712 )
2016
4
External beam radiation therapy for small cell carcinoma of the bladder. ( 26948133 )
2016
5
Small Cell Carcinomas of the Bladder Highly Express Somatostatin Receptor Type 2A: Impact on Prognosis and Treatment--A Multicenter Study of Urooncology Society, Turkey. ( 25906124 )
2016
6
Small cell carcinoma of the bladder. Report of two cases. ( 27772935 )
2016
7
Long-term outcomes of organ preservation in patients with small cell carcinoma of the bladder. ( 25660255 )
2015
8
Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. ( 25761779 )
2015
9
A Baffled Mind: A Mysterious Presentation of Small-Cell Carcinoma of the Bladder. ( 25733058 )
2015
10
Small cell carcinoma of the bladder: Our experience. ( 26331396 )
2015
11
Small cell carcinoma of the bladder. ( 25517085 )
2015
12
Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. ( 24036236 )
2014
13
Small cell carcinoma of the bladder associated with schistosomiasis: a case report. ( 25803993 )
2014
14
Treatment of Small Cell Carcinoma of the Bladder With Chemotherapy and Radiation after Transurethral Resection of a Bladder Tumor. ( 24517956 )
2014
15
Editorial comment from Dr Schreiber and Dr Rineer to local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. ( 23231721 )
2013
16
Editorial comment from Dr Ismaili to local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. ( 23231637 )
2013
17
Small cell carcinoma of the bladder: a search of the current literature. ( 23613409 )
2013
18
Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. ( 23231456 )
2013
19
Characterization and outcomes of small cell carcinoma of the bladder using the surveillance, epidemiology, and end results database. ( 22391430 )
2013
20
Editorial comment from Dr Koga to local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. ( 23231681 )
2013
21
Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). ( 23671508 )
2013
22
Treatment trends and outcomes of small-cell carcinoma of the bladder: in regard to Koay et al. (Int J Radiat Oncol Biol Phys 2011 Oct 20). ( 22385714 )
2012
23
Treatment trends and outcomes of small-cell carcinoma of the bladder. ( 22019246 )
2012
24
Immunohistochemical profile of urothelial and small cell carcinomas of the bladder. ( 21203907 )
2011
25
A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends. ( 21567387 )
2011
26
Small cell carcinoma of the bladder in transplant recipients: a report of 2 cases. ( 20174486 )
2010
27
Outcome of recurrent and metastatic small cell carcinoma of the bladder. ( 19500382 )
2009
28
Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. ( 18607595 )
2009
29
Dermatomyositis and small cell carcinoma of the bladder. ( 19826157 )
2009
30
Insights from a whole cystectomy specimen--association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ. ( 18547617 )
2008
31
[Case report: a case with small cell carcinoma of the bladder transformed from urothelial carcinoma]. ( 18516922 )
2008
32
Extrapulmonary small cell carcinoma of the bladder. ( 17270661 )
2007
33
Ectopic adrenocorticotropic hormone syndrome in a case of small cell carcinoma of the bladder manifesting as severe muscle weakness. ( 17095061 )
2006
34
Chromosome abnormalities and p53 expression in a small cell carcinoma of the bladder. ( 7889499 )
1995

Variations for Small Cell Carcinoma of the Bladder

Cosmic variations for Small Cell Carcinoma of the Bladder:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10704 TP53 urinary tract,bladder,carcinoma,small cell carcinoma c.844C>T p.R282W 26
2 COSM4167083 STAG2 urinary tract,bladder,carcinoma,small cell carcinoma c.1113C>G p.F371L 26
3 COSM4167082 urinary tract,bladder,carcinoma,small cell carcinoma c.1113C>G p.F371L 26
4 COSM550 KRAS urinary tract,bladder,carcinoma,undifferentiated carcinoma c.181C>G p.Q61E 23

Expression for Small Cell Carcinoma of the Bladder

Search GEO for disease gene expression data for Small Cell Carcinoma of the Bladder.

Pathways for Small Cell Carcinoma of the Bladder

Pathways related to Small Cell Carcinoma of the Bladder according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.31 ENO2 NKX2-1 SYP

GO Terms for Small Cell Carcinoma of the Bladder

Sources for Small Cell Carcinoma of the Bladder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....